Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Eiger Biopharmaceuticals

16/03/2023 21:32

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a
quarterly
adjusted loss of 57 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 54 cents per share.
    * Revenue fell 19.8% to $2.70 million from a year ago;
analysts
expected $4.43 million. 
    * Eiger BioPharmaceuticals Inc's reported EPS for the
quarter was
a loss of 57 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Eiger BioPharmaceuticals Inc shares had held steady so far
this
quarter.
    * The company reported a quarterly loss of $25.14 million.
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $9.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 16 at 09:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.54          -0.57          Missed
 Sep. 30 2022      -0.52          -0.62          Missed
 Jun. 30 2022      -0.61          -0.51          Beat
 Mar. 31 2022      -0.64          -0.64          Met